$HRTX
Heron Therapeutics Inc

2016 Q4 Form 10-K Financial Statement

#000119312517054088 Filed on February 23, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2016 Q2
Revenue $1.279M
YoY Change
Cost Of Revenue $35.00K
YoY Change
Gross Profit $1.244M
YoY Change
Gross Profit Margin 97.26%
Selling, General & Admin $18.54M $17.49M $15.78M
YoY Change 25.31% 112.02% 130.74%
% of Gross Profit 1490.51%
Research & Development $29.51M $30.24M $27.29M
YoY Change 81.42% 112.36% 68.69%
% of Gross Profit 2371.78%
Depreciation & Amortization $310.0K $300.0K $250.0K
YoY Change 34.78% 66.67% 47.06%
% of Gross Profit 24.92%
Operating Expenses $48.05M $47.73M $43.07M
YoY Change 54.69% 112.24% 87.13%
Operating Profit -$46.80M -$47.73M -$43.07M
YoY Change 112.24% 87.13%
Interest Expense $1.270M $886.0K $257.0K
YoY Change 414.17% 266.12% 8.44%
% of Operating Profit
Other Income/Expense, Net -$1.160M -$775.0K -$160.0K
YoY Change -235.59%
Pretax Income -$47.96M -$48.51M -$43.23M
YoY Change 53.52% 113.98% 87.06%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$47.96M -$48.51M -$43.23M
YoY Change 53.52% 113.96% 87.07%
Net Earnings / Revenue -3750.04%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.221M -$1.240M -$1.167M
COMMON SHARES
Basic Shares Outstanding 39.19M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $51.10M $88.90M $74.60M
YoY Change -61.05% -41.9% -56.5%
Cash & Equivalents $13.41M $45.64M $61.94M
Short-Term Investments $37.70M $43.30M $12.70M
Other Short-Term Assets $3.700M $3.100M $3.200M
YoY Change 2.78% 55.0% 68.42%
Inventory $5.340M $1.983M $3.312M
Prepaid Expenses
Receivables $1.960M
Other Receivables $0.00
Total Short-Term Assets $62.14M $93.97M $81.13M
YoY Change -53.88% -39.37% -53.22%
LONG-TERM ASSETS
Property, Plant & Equipment $5.076M $4.702M $4.471M
YoY Change 66.48% 57.68% 53.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $263.0K $130.0K $130.0K
YoY Change 484.44% -25.29% 0.0%
Total Long-Term Assets $5.339M $4.832M $4.601M
YoY Change 72.56% 53.11% 51.6%
TOTAL ASSETS
Total Short-Term Assets $62.14M $93.97M $81.13M
Total Long-Term Assets $5.339M $4.832M $4.601M
Total Assets $67.48M $98.81M $85.73M
YoY Change -51.05% -37.52% -51.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.814M $6.090M $8.661M
YoY Change 106.48% 122.67% 189.96%
Accrued Expenses $27.90M $22.10M $16.70M
YoY Change 96.48% 88.89% 42.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.900M $2.700M $2.600M
YoY Change 31.82% 28.57% 36.84%
Total Short-Term Liabilities $38.73M $30.93M $27.89M
YoY Change 96.27% 88.0% 68.11%
LONG-TERM LIABILITIES
Long-Term Debt $50.00M $50.00M $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $50.00M $50.00M $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $38.73M $30.93M $27.89M
Total Long-Term Liabilities $50.00M $50.00M $0.00
Total Liabilities $88.73M $80.93M $27.90M
YoY Change 349.62% 390.46% 68.07%
SHAREHOLDERS EQUITY
Retained Earnings -$586.0M -$538.0M -$489.5M
YoY Change 41.94% 40.99% 36.38%
Common Stock $394.0K $391.0K $390.0K
YoY Change 9.14% 8.91% 9.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$21.25M $17.88M $57.84M
YoY Change
Total Liabilities & Shareholders Equity $67.48M $98.81M $85.73M
YoY Change -51.05% -37.52% -51.42%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2016 Q2
OPERATING ACTIVITIES
Net Income -$47.96M -$48.51M -$43.23M
YoY Change 53.52% 113.96% 87.07%
Depreciation, Depletion And Amortization $310.0K $300.0K $250.0K
YoY Change 34.78% 66.67% 47.06%
Cash From Operating Activities -$38.52M -$36.12M -$27.11M
YoY Change 66.39% 81.6% 71.37%
INVESTING ACTIVITIES
Capital Expenditures -$690.0K -$540.0K -$1.080M
YoY Change 122.58% 116.0% 440.0%
Acquisitions
YoY Change
Other Investing Activities $5.500M -$30.62M $19.64M
YoY Change -109.8% 8083.33%
Cash From Investing Activities $4.810M -$31.15M $18.56M
YoY Change -108.53% 12360.0% 46300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.490M 50.96M 2.480M
YoY Change -15.34% 3085.0% -98.12%
NET CHANGE
Cash From Operating Activities -38.52M -36.12M -27.11M
Cash From Investing Activities 4.810M -31.15M 18.56M
Cash From Financing Activities 1.490M 50.96M 2.480M
Net Change In Cash -32.22M -16.31M -6.070M
YoY Change -58.59% -12.03% -105.23%
FREE CASH FLOW
Cash From Operating Activities -$38.52M -$36.12M -$27.11M
Capital Expenditures -$690.0K -$540.0K -$1.080M
Free Cash Flow -$37.83M -$35.58M -$26.03M
YoY Change 65.63% 81.16% 66.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2011Q2 hrtx Convertible Debt Issuable In Connection With Private Placement1
ConvertibleDebtIssuableInConnectionWithPrivatePlacement1
4500000
CY2016Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
2911000
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
13207000
CY2015Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
5231000
CY2016Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
342000
CY2015Q4 hrtx Accrued Sales Allowances Current
AccruedSalesAllowancesCurrent
CY2016 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
274000
CY2015 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
89000
CY2014 hrtx Amortization Of Shortterm Investment Premium
AmortizationOfShorttermInvestmentPremium
CY2011Q3 hrtx Common Shares Registered For Resale In Connection With Convertible Notes
CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes
3500000
CY2016Q4 hrtx Common Stock Underlying Convertible Notes Outstanding
CommonStockUnderlyingConvertibleNotesOutstanding
7521416
CY2015Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
2222000
CY2016 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7950
CY2015 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7950
CY2014 hrtx Defined Contribution Plan Maximum Annual Contributions By Employer Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsByEmployerPerEmployeeAmount
7800
CY2016 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
1864000
CY2015 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
CY2014 hrtx Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationAmount
CY2016Q4 hrtx Employee Stock Purchase Plan Available For Issuance
EmployeeStockPurchasePlanAvailableForIssuance
144600
CY2016 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
53798000
CY2015 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
31935000
CY2014 hrtx Income Tax Reconciliation Net Operating Loss Not Benefited
IncomeTaxReconciliationNetOperatingLossNotBenefited
25085000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016Q2 dei Entity Public Float
EntityPublicFloat
597117000
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
7976000
CY2015 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
1420000
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
55986000
CY2016 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14360000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25956000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
530617000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8067000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25956000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14360000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8067000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
689000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
624000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
573000
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
2038000
CY2016 hrtx Operating Lease Annual Rent Expense
OperatingLeaseAnnualRentExpense
2000000
CY2016 hrtx Payments Of Sales Returns And Allowances Goods
PaymentsOfSalesReturnsAndAllowancesGoods
0
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6814000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3300000
CY2016Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
1039000
CY2015Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
36000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1960000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
CY2016Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3474000
CY2015Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2965000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4703000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3914000
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
116000
CY2015Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
61000
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
2236000
CY2015Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1863000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6614000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5552000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-40000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
564343000
CY2015 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
905000
CY2016Q4 us-gaap Assets
Assets
67482000
CY2015Q4 us-gaap Assets
Assets
137845000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
62143000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
134751000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
49217000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
124075000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37741000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
56026000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
37724000
CY2015 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2014 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-97631000
CY2015 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2016 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2015 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2016 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
23000
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
40000
CY2016 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
17000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75180000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72675000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72287000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13414000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-61766000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2505000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
388000
CY2016Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
51100000
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
1000000
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
600000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
22764940
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39355000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36106000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39355000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36106000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
394000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
361000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-173120000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76367000
CY2016 us-gaap Depreciation
Depreciation
1100000
CY2015 us-gaap Depreciation
Depreciation
700000
CY2014 us-gaap Depreciation
Depreciation
600000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1099000
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Concentration of Credit Risk</div></div></div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> be in excess of insured limits. We <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> also invest our excess cash in money market funds, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</div></div> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div>&nbsp;</div> <div style=" MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Sales to ASD Specialty Healthcare, Inc., Cardinal Health, Inc. and McKesson Specialty Care Distribution Corporation each accounted for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> or more of our net revenues for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div>&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The loss of any of these customers could materially and adversely affect our business, results of operations, financial condition and cash flows. </div></div></div></div></div></div></div></div>
CY2016Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1700000
CY2015Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
200000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2016Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
35000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
CY2014 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
309000
CY2015 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
328000
CY2016 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
348000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1099000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
168890000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
113717000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
138727000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
94465000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
3204000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1345000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
16687000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11181000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
10272000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6726000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
168890000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
113717000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
CY2014 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.5
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
734000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
578000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.22
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.56
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.95
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.87
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8414000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4828000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
86400000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y328D
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-9000
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
118000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-17000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5367000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4774000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5333000
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5892000
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3587000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4082000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4127000
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6599000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21366000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18395000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11020000
CY2016Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-33312000
CY2016Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-43066000
CY2016Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-47734000
CY2016Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-46803000
CY2015Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-20360000
CY2015Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-23014000
CY2015Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-22491000
CY2015Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-31060000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-58868000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-33181000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-25965000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2694000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
894000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
551000
CY2016 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
512000
CY2015 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
352000
CY2014 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
329000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3514000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
751000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1285000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1960000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1099000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
338000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2443000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
419000
CY2016Q1 us-gaap Interest Expense
InterestExpense
251000
CY2016Q2 us-gaap Interest Expense
InterestExpense
257000
CY2016Q3 us-gaap Interest Expense
InterestExpense
886000
CY2016Q4 us-gaap Interest Expense
InterestExpense
1270000
CY2016Q4 us-gaap Inventory Net
InventoryNet
5340000
CY2015Q4 us-gaap Inventory Net
InventoryNet
CY2015Q1 us-gaap Interest Expense
InterestExpense
232000
CY2015Q2 us-gaap Interest Expense
InterestExpense
237000
CY2015Q3 us-gaap Interest Expense
InterestExpense
242000
CY2015Q4 us-gaap Interest Expense
InterestExpense
247000
CY2016 us-gaap Interest Expense
InterestExpense
2664000
CY2015 us-gaap Interest Expense
InterestExpense
958000
CY2014 us-gaap Interest Expense
InterestExpense
887000
CY2016 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
400000
CY2015 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
300000
CY2014 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
300000
CY2016 us-gaap Interest Paid
InterestPaid
1622000
CY2015 us-gaap Interest Paid
InterestPaid
CY2014 us-gaap Interest Paid
InterestPaid
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2589000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
CY2015Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
22000
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
CY2016 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3586000
CY2015 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2097000
CY2014 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
165000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5340000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
CY2016 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2482000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1551000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2876000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1647000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1104000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
118000
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
97000
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
111000
CY2016Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
119000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-96925000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-74561000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78526000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60282000
CY2015Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
61000
CY2015Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
65000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2100000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1500000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1400000
CY2016Q4 us-gaap Liabilities
Liabilities
88733000
CY2015Q4 us-gaap Liabilities
Liabilities
19735000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67482000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
137845000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38733000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19735000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
57455000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
137991000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62108000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14876000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56960000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1438000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-134097000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-173143000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-97591000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-76367000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-33445000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-43226000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-48509000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-47963000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-20570000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23107000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-22672000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-31242000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2228000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-666000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1806000
CY2016Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
50000000
CY2015Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
CY2016 us-gaap Operating Expenses
OperatingExpenses
172194000
CY2015 us-gaap Operating Expenses
OperatingExpenses
96925000
CY2014 us-gaap Operating Expenses
OperatingExpenses
74561000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-170915000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
13058000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2259000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1466000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1424000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2016Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2015Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
436000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
292000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-919000
CY2016Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
88000
CY2015Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
143000
CY2016 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
-61329000
CY2015 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
CY2014 us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
CY2016 us-gaap Payments For Restructuring
PaymentsForRestructuring
2200000
CY2016 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
43318000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
56115000
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3135000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1438000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1086000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1824000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2553000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3532000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6288000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4154000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
263000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
23000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-40000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3705000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3585000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
771000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
257000
CY2014 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
91000
CY2016 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
CY2015 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
128199000
CY2014 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
58916000
CY2016 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50000000
CY2015 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2014 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
241000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6684000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9535000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3101000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11690000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8601000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5076000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3049000
CY2016 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
CY2016Q4 us-gaap Purchase Obligation
PurchaseObligation
6700000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16092000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27286000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30242000
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29505000
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14504000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16175000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14241000
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16263000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
103125000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61183000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54833000
CY2016Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
10400000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
2704000
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-585971000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-412828000
CY2016 us-gaap Sales Allowances Goods
SalesAllowancesGoods
342000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2016Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1279000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1279000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
CY2015Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4123000
CY2015Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8198000
CY2016 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
47668000
CY2016Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11853000
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11006000
CY2016Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12159000
CY2016Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
12650000
CY2015Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2269000
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2757000
CY2015 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
17347000
CY2014 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8708000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
25956000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
14360000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
8067000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2653548
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4356665
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2587392
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2237901
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.66
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.72
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.01
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10400000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13900000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4293
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
862085
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
575178
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
711910
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
9.88
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.42
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
22.43
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
707617
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3181001
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2134505
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4920661
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16900000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
46600000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11845376
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6355681
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7918004
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8434988
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.22
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.64
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.44
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11234529
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8059481
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7841074
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.32
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.38
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.69
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.34
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.15
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.37
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
35.09
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.35
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.40
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
28.95
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
15.98
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
128199000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3101000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9535000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6684000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-21251000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
118110000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
68945000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
63062000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2016 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
3.80
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4356665
CY2016Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
11845376
CY2016 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
102.40
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y109D
CY2016Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
11.66
CY2016Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
14.44
CY2016 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y219D
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
798363
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
756593
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1042343
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
91000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
257000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
771000
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
100000
CY2015Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
100000
CY2016Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
4600000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include revenue recognition, inventory, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div>
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
55200000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
40400000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37925000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33081000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26569000

Files In Submission

Name View Source Status
0001193125-17-054088-index-headers.html Edgar Link pending
0001193125-17-054088-index.html Edgar Link pending
0001193125-17-054088.txt Edgar Link pending
0001193125-17-054088-xbrl.zip Edgar Link pending
d347497d10k.htm Edgar Link pending
d347497dex231.htm Edgar Link pending
d347497dex311.htm Edgar Link pending
d347497dex312.htm Edgar Link pending
d347497dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g347497g67f46.jpg Edgar Link pending
hrtx-20161231.xml Edgar Link completed
hrtx-20161231.xsd Edgar Link pending
hrtx-20161231_cal.xml Edgar Link unprocessable
hrtx-20161231_def.xml Edgar Link unprocessable
hrtx-20161231_lab.xml Edgar Link unprocessable
hrtx-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending